Barbara Schilberg

Managing Director and Chief Executive Officer

“We have a tremendous opportunity to galvanize economic growth in southeastern Pennsylvania by building on our depth and breadth in the life sciences, particularly in biopharmaceuticals and medical devices. The funding from the Commonwealth allows BioAdvance to provide critical capital and other support to help entrepreneurs move science from the laboratory into successful businesses.”

Ms. Schilberg has more than 30 years of experience working with academic technologies and start-up companies in the life sciences sector. Under her leadership as CEO, BioAdvance has committed $44 million to 58 seed-stage companies and 32 pre-seed projects focusing in areas including Alzheimer’s disease, cancer, diabetes, obesity and infectious diseases. The BioAdvance portfolio companies have leveraged over $2.71 billion in subsequent capital from venture capital, grants, collaborations, M&A activity and product revenues. Twelve portfolio companies have been acquired and two companies have completed an initial public offering.

Ms. Schilberg is, or has served as a board member or observer for several BioAdvance portfolio companies including Protez, Avid, Immunome, Jenrin Discovery, Merganser, Novira Pharmaceuticals, Ossianix, Mebias Discovery, One Health, Keriton, Pillo Health, ENB Therapeutics and Palvella Therapeutics. In addition to her role at BioAdvance, Ms. Schilberg serves on various boards or advisory boards, including the Alliance for Women Entrepreneurs (AWE), the Drexel-Coulter Translational Research Partnership, the Roy and Diana Vagelos Life Sciences & Management Program at the University of Pennsylvania, the Penn Medicine Research Council Meeting, the University City Keystone Innovation Zone, and the University City Science Center’s Phase 1 Ventures. She is the recipient of the Iris Newman Award from AWE and the Hubert J.P. Schoemaker Leadership Award from Life Sciences Pennsylvania.

As a senior executive with four emerging life sciences companies, Ms. Schilberg’s prior experience provides significant insight into the key elements needed to build successful companies including public and private financings, intellectual property protection, corporate partnering arrangements and the management of research programs. She joined Cephalon in 1994 as Senior Vice President and General Counsel and as a member of the executive committee. As part of her responsibilities, she led a multi-disciplinary team charged with completing Phase III clinical trials and preparing a new drug application for PROVIGIL® (modafinil), which was approved by the FDA in December 1999. She joined Incara Pharmaceuticals in 1998 as Executive Vice President and General Counsel, where she managed a research operation in Princeton, NJ engaged in discovering new antibacterial therapeutics. She continued in that capacity after the operation’s acquisition by Advanced Medicine (now Theravance) in 2000. Ms. Schilberg also served as Vice President and General Counsel at Locus Discovery, Inc., an emerging pharmaceutical company in Blue Bell, PA engaged in computational drug design.

Before joining industry, Ms. Schilberg specialized in representing biopharmaceutical companies and research institutions in public and private financings and the commercialization of technology, as a partner in the Philadelphia office of Morgan, Lewis & Bockius. Ms. Schilberg received a J.D. from the University of Virginia and clerked with the Honorable Edward R. Becker, formerly Senior Judge of the U.S. Court of Appeals for the Third Circuit.

 

Other Team Members